AbbVie Inc.

ABBV

Held by 1 specialist biotech fund

Share on X

Fund Holdings

Deerfield Management

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Deerfield ManagementNEWFeb 17, 2026

Shares: 2,014Value: $460K

# Signal Note: Deerfield Initiates AbbVie Position Deerfield's new $460K position in ABBV likely reflects conviction in near-term catalysts around AbbVie's immunology franchise, particularly Rinvoq (upadacitinib) across multiple indications or upcoming data readouts in 2024-2025. The healthcare-focused multi-strategy fund's entry suggests either an undervalued risk/reward on near-term clinical/commercial inflection or positioning ahead of known milestone announcements; monitor for pipeline updates (particularly in atopic dermatitis, UC/Crohn's, or RA label expansions) to confirm thesis.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

RDNT1 fund VTR1 fund PHVS1 fund PMVP1 fund ALHC1 fund ATRC1 fund BCRX1 fund NBIX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: